OBJECTIVE: To investigate whether ventilator-associated pneumonia (VAP) is a true cause of mortality in the intensive care unit setting. METHODS: We performed a meta-analysis of available data without time restrictions. A conservative random effects model was employed to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Of 968 retrieved reports, 44 studies fulfilled our inclusion criteria. Presence, as opposed to absence, of VAP was associated with higher mortality in the ICU setting (OR 1.96, 95%CI 1.26-3.04). This result persisted when matched case-control studies (OR 1.73, 95%CI 1.23-2.45) or studies in which VAP was microbiologically confirmed in all patients (OR 2.20, 95%CI 1.01-4.81) were evaluated separately. VAP continued to be associated with higher mortality when the impact of immune suppression was controlled. VAP was not associated with higher mortality in the subgroup analysis of studies including patients who received appropriate initial antimicrobial treatment (OR 1.64, 95%CI 0.68-3.96). CONCLUSION: Presence, compared to absence, of VAP seems to be associated with higher mortality in critically ill patients. Appropriateness of initial antimicrobial treatment in such patients may moderate this association.
OBJECTIVE: To investigate whether ventilator-associated pneumonia (VAP) is a true cause of mortality in the intensive care unit setting. METHODS: We performed a meta-analysis of available data without time restrictions. A conservative random effects model was employed to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Of 968 retrieved reports, 44 studies fulfilled our inclusion criteria. Presence, as opposed to absence, of VAP was associated with higher mortality in the ICU setting (OR 1.96, 95%CI 1.26-3.04). This result persisted when matched case-control studies (OR 1.73, 95%CI 1.23-2.45) or studies in which VAP was microbiologically confirmed in all patients (OR 2.20, 95%CI 1.01-4.81) were evaluated separately. VAP continued to be associated with higher mortality when the impact of immune suppression was controlled. VAP was not associated with higher mortality in the subgroup analysis of studies including patients who received appropriate initial antimicrobial treatment (OR 1.64, 95%CI 0.68-3.96). CONCLUSION: Presence, compared to absence, of VAP seems to be associated with higher mortality in critically illpatients. Appropriateness of initial antimicrobial treatment in such patients may moderate this association.
Authors: Kathleen Speck; Nishi Rawat; Noah C Weiner; Haddis G Tujuba; Donna Farley; Sean Berenholtz Journal: Am J Infect Control Date: 2016-02-10 Impact factor: 2.918
Authors: N Cobos-Trigueros; M Rinaudo; M Solé; P Castro; J Pumarol; C Hernández; S Fernández; J M Nicolás; J Mallolas; J Vila; L Morata; J M Gatell; A Soriano; J Mensa; J A Martínez Journal: Eur J Clin Microbiol Infect Dis Date: 2013-10-23 Impact factor: 3.267
Authors: Stephen W Davies; Jimmy T Efird; Christopher A Guidry; Tjasa Hranjec; Rosemarie Metzger; Brian R Swenson; Robert G Sawyer Journal: J Trauma Acute Care Surg Date: 2014-10 Impact factor: 3.313
Authors: Rocío Álvarez-Marín; Rafael López-Rojas; Juan Antonio Márquez; María José Gómez; José Molina; José Miguel Cisneros; Carlos Ortiz-Leyba; Javier Aznar; José Garnacho-Montero; Jerónimo Pachón Journal: PLoS One Date: 2016-12-19 Impact factor: 3.240